CMDE Unveils 2026–2027 Roadmap for Medical Device Registration Guidelines, Emphasizing AI, IVDs, and High-Risk Technologies

On April 24, 2026, China’s Center for Medical Device Evaluation (CMDE) released its Announcement on the Development Plan for Medical Device Registration Review Guidelines (No. 14 of 2026), outlining a comprehensive roadmap for drafting and revising regulatory guidance through 2026–2027.

The plan provides early insight into CMDE’s regulatory priorities, with a clear focus on artificial intelligence (AI)-enabled devices, in vitro diagnostics (IVDs), and high-risk or technically complex products. It also signals a shift toward more detailed, product-specific review requirements, particularly in areas where clinical evidence expectations are rapidly evolving.

For international manufacturers the roadmap serves as an important forward-looking tool. It not only highlights where new guidance will emerge, but also indicates how regulatory expectations may tighten across both innovative and established device categories.

CMDE Expands Medical Device Guideline Framework at Scale

The plan signals a broad expansion of China’s medical device registration review framework. It covers 275 guideline projects across Class III and Class II medical devices, including both new guidance documents and revisions to existing ones.

In 2026, CMDE plans to draft 44 new guidelines and revise 12 existing guidelines for Class III medical devices. These projects cover high-risk and technically complex products, including implantable devices, AI-assisted diagnostics, cardiovascular interventions, high-risk IVDs, and advanced therapeutic systems.

For Class II devices, the plan includes 84 new guidelines in 2026 and 53 new guidelines in 2027. It also includes 82 planned revisions for Class II device guidelines in 2026. These updates cover a wide range of commonly used clinical devices, IVD instruments, reagents, monitoring products, rehabilitation technologies, and passive surgical instruments.

The stated purpose is to further advance scientific, standardized, and internationally oriented medical device registration review while proactively defining review expectations for emerging and higher-risk product areas.

Class III Devices Target High-Risk and Innovative Technologies

The Class III portion of the plan focuses on products with higher clinical risk, greater technical complexity, or rapidly evolving evidence expectations. It also includes several product-specific clinical evaluation guidelines, which may be especially relevant for overseas manufacturers preparing China medical device registration submissions.

Neuromodulation, Implantables, and Advanced Therapies

CMDE plans new guidelines for implantable neurostimulation electrodes and neurostimulation programmable chargers. The plan also includes guidance projects for implantable or surgically used products such as patellar claws, cranial clips and locks, dental abutments, breast tissue markers, insulin pump reservoirs, insulin pump subcutaneous infusion sets, and artificial blood vessels.

Other high-complexity technologies include:

• Laser photodynamic therapy machines
• Picosecond Nd:YAG laser treatment devices
• Femtosecond laser treatment systems
• Hyperbaric oxygen chamber equipment,
• Recombinant collagen products for plastic and aesthetic use
• Medical radiofrequency treatment devices

Cardiovascular, Embolic, and Interventional Products

The plan includes multiple interventional and cardiovascular device categories. These include:

• Intracranial liquid embolization devices
• Specialty balloon dilatation catheters
• Peripheral thrombectomy aspiration catheters
• Embolic microspheres
• Intravascular shockwave treatment systems
• Artificial blood vessels
• Cardiac arrest solution perfusion devices

This level of product-level detail suggests CMDE is moving beyond broad technology categories and toward more specific registration review expectations for individual device types.

AI-Assisted Diagnostics and Software-Based Devices

AI medical devices are a prominent Class III focus. CMDE plans new clinical evaluation guidelines for AI-assisted diagnostic medical devices and AI multi-class assisted decision-making medical devices.

The plan also includes a revision of the existing AI medical device registration review guideline. This should be closely monitored by overseas manufacturers of software-based medical devices, AI diagnostic systems, and decision-support products seeking China market entry.

IVD Self-Testing, Molecular Diagnostics, and High-Risk Assays

Class III IVD projects include both infectious disease and molecular diagnostic products. New guideline projects cover:

• Syphilis antibody detection reagents
• Ureaplasma urealyticum nucleic acid detection reagents
• norovirus nucleic acid detection reagents
• Hepatitis B surface antigen detection reagents
• Cervical cancer methylation detection reagents.

The plan also includes clinical trial guidelines for consumer self-testing HIV antibody detection reagents and consumer self-testing respiratory virus antigen detection reagents. These projects are particularly relevant for overseas IVD manufacturers developing direct-to-consumer or home-use testing products for China.

CMDE also plans revisions for several Class III IVD-related guidelines, including:

• Helicobacter pylori antigen and antibody detection reagents
• Anti-human globulin detection reagents
• Enterovirus nucleic acid detection reagents
• Tuberculosis-specific cellular immune response detection reagents
• Tumor-related mutation gene detection reagents using high-throughput sequencing.

Class II Devices See Broad and Diverse Regulatory Coverage

The Class II portion of the plan is extensive and diverse. It covers respiratory products, monitoring devices, rehabilitation systems, traditional Chinese medicine technologies, passive surgical instruments, consumables, IVD instruments, and IVD reagents.

Respiratory, Anesthesia, and Monitoring Devices

CMDE plans new Class II guidelines for products such as:

• Carbon dioxide monitors
• Pulse oximeter sensors
• Defibrillation electrodes
• Oxygen generation equipment
• Exhalation flow measurement devices
• Exhaled nitric oxide analyzers
• Anesthesia waste gas collectors
• Pacemaker system analyzers
• Thyroid function analyzers

The Class II revision plan also includes widely used products such as pulmonary ventilation function testing devices, sleep respiratory monitoring products, resuscitators, heat and moisture exchangers, mesh nebulizers, injection pumps, and anesthesia masks.

Rehabilitation and Traditional Chinese Medicine Technologies

T The plan includes several rehabilitation and traditional Chinese medicine-related device categories. These include:

• Cognitive rehabilitation devices
• Visual rehabilitation devices
• Balance training devices
• Vibration training devices
• Warm needle therapy devices
• Moxibustion instruments
• Moxibustion therapy tools
• Acupoint magnetic therapy devices
• Traditional Chinese medicine auxiliary diagnostic software

This coverage shows that CMDE’s guideline development plan is not limited to high-tech products. It also extends to localized clinical technologies and frequently used rehabilitation products.

Passive Surgical Instruments and Consumables

CMDE plans new Class II guidelines for a wide range of passive surgical instruments and consumables. Examples include:

• Puncture needles
• Dilators
• Silicone encircling bands
• Intraocular lens injectors
• Disposable balloon uterine stents
• Spinal surgery access instruments
• Burrs
• Vertebroplasty guidance systems
• Disposable endoscopic sleeves
• Biopsy guns
• Rectal tubes
• Rectal manometry catheters
• Negative pressure drainage devices and components
• Sample collection devices.

For 2027, additional Class II projects include:

• Catheter sheaths
• Connector valves
• Orthopedic saws
• Annulus fibrosus suturing devices
• External cranial drainage collection devices
• Thoracic drainage devices
• In vitro drainage and suction tubes
• Surgical non-woven dressings
• Surgical sponge dressings
• Sterile bite blocks
• Vaginal packing materials
• Disposable thread-embedding needles

IVD Instruments, Reagents, and Routine Diagnostics

The plan places strong emphasis on IVD instruments and routine diagnostic reagents. New Class II IVD-related projects include:

• Parathyroid hormone detection reagents
• Testosterone test kits
• Thyroglobulin reagents
• Sex hormone-binding globulin reagents
• Cholinesterase reagents
• Lipase reagents
• Myeloperoxidase reagents
• Ammonia reagents
• Anticardiolipin antibody reagents
• Multiple enzyme and metabolic marker assays

Instrument projects include:

• Blood cell morphology analyzers
• Flow cytometers
• Electrolyte analyzers
• Microbial culture monitoring instruments
• Bacterial endotoxin detectors
• Helicobacter pylori analyzers
• Image scanning instruments
• Urinalysis systems
• Glycosylated hemoglobin chromatography columns
• Osmometry instruments
• Biochemical immunoassay analyzers
• Antimicrobial susceptibility analyzers
• Feces analyzers
• Sperm analyzers
• Reproductive tract secretion analyzers
• Biochip analyzers

Regulatory Opportunities and Challenges for Overseas Manufacturers

The plan gives foreign manufacturers earlier visibility into CMDE’s planned review priorities. Because it is a development plan, not the final text of each individual guideline, companies should treat it as an early warning tool for regulatory planning.

Its main value is improved predictability. Manufacturers can identify whether current or pipeline products fall within planned new or revised guidance areas and begin preparing technical documentation, testing plans, clinical evaluation strategies, and China-specific registration timelines earlier.

The revision projects also deserve close attention. They show that CMDE is updating expectations not only for innovative technologies, but also for established product categories. For overseas manufacturers, this may affect renewal planning, change registration, technical documentation updates, and evidence strategies for products already approved or under review in China.

As individual guidelines are finalized, manufacturers may need to align submissions with more detailed review expectations. This will be particularly important for AI-assisted diagnostics, self-testing IVDs, implantable devices, embolic materials, nanomaterial-based devices, and products subject to clinical evaluation guidance.

Recommended Actions to Align with CMDE Requirements

Overseas manufacturers should assess the plan now and determine whether any current or pipeline products are affected. Early preparation can reduce the risk of registration delays, avoid incomplete submissions, and support more efficient communication with local partners.

Identify Impacted Products Early

Manufacturers should map product portfolios against the published CMDE lists. Class III devices planned for 2026 deserve particular attention because they include high-risk products and several clinical evaluation guidance projects.

Track Draft and Final Guideline Development

Companies should monitor draft and final versions of relevant CMDE guidelines as they are released. The published plan identifies the projects, but the detailed technical expectations will appear in the individual guideline documents.

Adjust Registration Strategies and Timelines

Because new guidelines may take effect immediately upon finalization, manufacturers should align product design, validation, and documentation with draft requirements during development — not after approval.

In particular, manufacturers should assess whether planned guidelines may affect performance testing, biological evaluation, animal testing, clinical evaluation, clinical trial planning, software documentation, or IVD analytical and clinical evidence

Strengthen Local Compliance Capabilities

For complex technologies such as AI diagnostics, neuromodulation systems, and embolic materials, early collaboration with local CROs and regulatory experts is critical to ensure complete and compliant submissions.

Final Thoughts: Implications for China Medical Device Market Entry

The CMDE plan reinforces the importance of proactive regulatory planning for China medical device registration. It gives manufacturers a clear view of where review expectations are likely to become more specific, especially in AI, IVDs, implants, interventional devices, advanced materials, and routine diagnostic systems.

For overseas manufacturers, the key challenge is not only understanding whether a product is listed. Companies must also determine how future guidance may affect product classification, testing plans, clinical evidence, registration timing, and post-approval compliance.

That is why early portfolio mapping and technical gap analysis are important. With regulatory monitoring, product classification mapping, technical documentation review, clinical evaluation support, and registration strategy planning, Cisema supports international companies navigating China’s increasingly detailed medical device regulatory landscape. To assess your product pipeline and align early with China’s evolving regulatory requirements, contact Cisema today.

Further Information

• Explore Cisema’s services for medical device registration in China.

References

Announcement on the Development Plan for Guiding Principles for Medical Device Registration Review …

‍